Quick Answer
Pacira BioSciences, Inc. reported Long-Term Debt of $372.19 million for fiscal year 2025.
Pacira BioSciences, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $372.19M | -3.0% |
| 2024 | $383.55M | — |
| 2013 | $0.00 | -100.0% |
| 2012 | $25.19M | +35.9% |
| 2011 | $18.54M | -15.2% |
| 2010 | $21.87M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $376.72M | — | -1.8% |
| December 31, 2024 | $383.55M | — | — |
| September 30, 2013 | $0.00 | -100.0% | -100.0% |
| June 30, 2013 | $96.89M | +292.8% | +1.1% |
| March 31, 2013 | $95.86M | +305.6% | +280.5% |
| December 31, 2012 | $25.19M | +35.9% | +1.0% |
| September 30, 2012 | $24.93M | +21.0% | +1.1% |
| June 30, 2012 | $24.67M | +21.2% | +4.4% |
- Pacira BioSciences, Inc. showed a decrease of -3.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2010–2025 period, Pacira BioSciences, Inc.’s long-term debt has grown by 1601.9% (from $21.87 million to $372.19 million).
- The most recent figure is from Pacira BioSciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: